ABIONYX Pharma SA ABNX
EURONEXT · France · Health Technology
€1.71-0.05 (-2.95%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
TOULOUSE, France & FULLERTON, Calif., September 23, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today announced its financial results for the first half of 2026.
TOULOUSE, France & FULLERTON, Calif., September 10, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, announces the establishment of a strategic partnership with TEXCELL, a division of ABL Diagnostics, for the viral safety and clearance testing of its biopharmaceutical development.
WOIPPY, France, September 10, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD - ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, today announced the conclusion of a strategic partnership with ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies in sepsis and intensive care, based on an exclusive apoA-I-based technology plat
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.